REGN Stock Summary and Trading Ideas (Regeneron Pharmaceuticals | NASDAQ:REGN)

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals trades on the NASDAQ stock market under the symbol REGN.

As of October 31, 2024, REGN stock price declined to $838.20 with 2,188,238 million shares trading.

REGN has a beta of 0.77, meaning it tends to be less sensitive to market movements. REGN has a correlation of 0.19 to the broad based SPY ETF.

REGN has a market cap of $92.36 billion. This is considered a Large Cap stock.

Last quarter Regeneron Pharmaceuticals reported $4 billion in Revenue and $11.56 earnings per share. This beat revenue expectation by $187 million and exceeded earnings estimates by $1.03.

In the last 3 years, REGN traded as high as $1,211.20 and as low as $538.01.

The top ETF exchange traded funds that REGN belongs to (by Net Assets): VTI, VOO, QQQ, SPY, IVV.

REGN has underperformed the market in the last year with a price return of +7.8% while the SPY ETF gained +38.5%. REGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -22.2% and -16.8%, respectively, while the SPY returned +5.2% and -2.3%, respectively.

REGN support price is $909.37 and resistance is $936.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that REGN shares will trade within this expected range on the day.